HIV Studies

Daybreak 2 (Switch)

EU CT Nummer: 2025-524336-19

Recruitment approx. Fall 2026

Study Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice-Yearly in comparison to oral ART continuation.

We are looking for patients with:

  • Any stable oral ART since 6 months
  • HIV-RNA <50 cop/ml for at least 6 months
  • no previous virological failure 

If you are interested in the study, please speak to your family doctor or infectiologist. You can also contact us directly by email or via the contact form for more information.

Contact

Islend 1

EU CT Nummer: 2024-514046-37 

Recruitment closed

NEW: once weekly Lenacapavir + Islatravir

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide inVirologically Suppressed People With HIV-1

We are looking for patients with:

  • Bictarvy since 6 months
  • HIV-RNA <50 cop/ml for at least 6 months
  • no previous virological failure 

If you are interested in the study, please speak to your family doctor or infectiologist. You can also contact us directly by email or via the contact form for more information.

Contact

VOGUE

EU CT Nummer: 2023-504993-40-00

Recruitment closed

 

A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug regimen for the treatment of HIV-1 in adults who

have not previously taken antiretroviral therapy.

We are looking for patients with:

  • initial HIV diagnosis

  • HIV-1 positive

  • CD4 >200
  • no opportunistic infections (local Kaposi ok)
  • Hbs-Ag neg; HBV-DNA neg

If you are interested in the study, please speak to your family doctor or infectiologist. You can also contact us directly by email or via the contact form for more information.

Contact